Get startedLog in
    Picture of JW (Cayman) Therapeutics Co logo

    2126 — JW (Cayman) Therapeutics Co Cashflow Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for JW (Cayman) Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-1,664-702-846-768-591
    Depreciation
    Amortisation
    Non-Cash Items1,35934.8231233169
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital20.158.1-9.1236.9-1.38
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-261-561-537-398-333
    Capital Expenditures-130-137-101-14.6-15.4
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items38.30-23.524.50
    Sale of Business
    Sale of Fixed Assets
    Other Investing Cash Flow
    Cash from Investing Activities-91.9-137-1249.9-15.4
    Financing Cash Flow Items-27.3-18.3-6.79-12.4-12.2
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities2,859-30.61120.27590.5
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash2,376-796-451-377-249